

IDEA Workshop

Characterization & Categorization of Fragrance Allergens

September 23-25th, 2014

Feedback from the Communication TF and outlook into the future

Nicola Gilmore & Peter Griem

Workshop Characterisation of Allergens

August 2013

- Breakout Group II - How to improve the diagnostic process for determining the culprit in ACD so as to enhance industry's responsiveness

Key concerns

1. Improve RA
2. ACD Culprit
3. Using clinical epidemiology data for warning/post-marketing surveillance
4. Cosmetovigilance data – may help identify materials that should be evaluated in the clinic

Establish Process for Obtaining Diagnostic Data

- Working process to identify (fragrance) allergens that is well-publicized to both industry & dermatology communities (global)
 - Easy way to identify individual(s) in consumer product companies for the dermatologist to contact on a worldwide basis
 - Role for associations?
 - Standardized method of supplying properly identified samples to dermatologist
 - Formalize dilutions
 - Correctly labelled ingredients with name
 - Formalize vehicles
 - Formal mechanism for obtaining results from the dermatologist
 - Agreement on information needed to help improve the RA
 - Formal mechanism to review data on (fragrance) allergens (workshop?)
 - Potential actions: revising RA; revising risk management, pro-active surveillance
 - Include cosmetovigilance data in the review
- Identifying potential pro-active surveillance fragrance materials for dermatologists to test (via NACDG; EECDRG; ESCD fragrance group, ICDRG, National groups of dermatologists (e.g. GERDA), others?)

Patient diagnosis & information





Vigilance



CONSUMER PROTECTION

NEW EMERGING ALLERGENS



COMMUNICATION TF

Kick-off Telco June 4th, 2014

- **Remit of TF:** develop information exchange procedure to improve communication between industry and the dermatology community
- Industry → Dermatologists: provide reference materials to help the diagnosis of contact dermatitis
- Dermatologists → Industry: provide results of clinical testing as feedback into risk assessment/management process

COMMUNICATION TF

- **Participants:**
 - Hans Bender (Chairman)
 - Michèle Elbaz (Chanel)
 - Peter Griem (Symrise)
 - Maya Krasteva (L'Oréal)
 - Fred Lebreux (IDEA Management Team)
 - Florian Schellauf (Cosmetics Europe)
 - Scott Schneider (Firmenich)
 - Matthias Vey (IDEA Management Team)

COMMUNICATION TF

- **Initial focus:** How can we be more pro-active in supporting diagnostic procedure and obtain feedback on materials and products eliciting reactions
- **Existing publication:** process how samples can be requested by dermatologists and provided by the industry
Cadby et al., Flavour Fragr. J. 26 (2011) 2-6
- **TF comment:** too general, should be more specific to meet industry's needs, e.g. description of preparation of fractions
- **Proposed action:** review and rewrite article with input from Dermatologists and submit to Contact Dermatitis

COMMUNICATION TF

■ **Potential Points to be revised:**

- Process description how dermatologists can request samples and how these should be prepared by industry
- Practical guidance how dermatologists should contact industry to get support
- Agreement on how clinical results should be shared with industry
- Agreement on appropriate risk management measures should be taken to correct problematic situations

COMMUNICATION TF

■ TF proposal:

- Broader information of dermatologists of possibility to receive individuals allergens, e.g. via ESCD congresses
- Inform Dermatologists about this initiative on a one-to-one basis, e.g., by website, blog, Twitter account
- Inform affected consumers of advantages of knowing either specific allergens, e.g. via (IDEA) website

COMMUNICATION TF

- **TF questions**
- Would these types of resources be helpful in supporting the diagnostic procedure?
- Industry observation: scarce follow-up patch tests with individual allergens. Why?
 - Follow-up testing may be too time-consuming, costly for the clinic and too unpleasant/cumbersome for the patient?
 - provision of allergen samples by industry might be too slow?
- Team currently consists of Industry representatives only. Cannot progress without correct input.
 - Call for interest to Dermatologists to participate in Communication TF

COMMUNICATION TF

Future perspectives

- Vigilance: to do this properly we need to have frameworks in place
 - Need to agree what information needs shared
 - Eg: Schnuch comment on final TF minutes: dermatologists need to be informed when new [sensitising] chemicals are introduced into the market
 - Industry awareness of medically confirmed ACD to products
 - How do we get more pro-activity so we can act on information?
 - Eg: providing samples for new / existing materials for investigation in key centers?
 - How do we ensure dialogue between all parties to put pieces together?
 - Eg: forum for information exchange?

Patient diagnosis & information



CONSUMER PROTECTION

Vigilance



NEW EMERGING ALLERGENS

